Arginine
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
Arginine: From an Unspecified Original Indication to Gastroparesis
One-Sentence Summary
Arginine is an amino acid supplied in Australia as an oral powder (Arginine 5000) and as an oral liquid nutritional product (Cubitan), but no approved indication text is available in the data compiled for this report. The TxGNN model predicts it may be useful for gastroparesis. Support is limited to 0 clinical trials and 9 publications, all preclinical animal studies or case reports, so this is a research question rather than a treatment recommendation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no approved indication text in the compiled data) |
| Predicted New Indication | Gastroparesis |
| TxGNN Prediction Score | 0.9942 |
| Evidence Level | L4 |
| Australia Market Status | Listed on the PBS Schedule (2 of 2 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 2 (valid: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for arginine is not available in the compiled data. The rationale below rests on general nitric oxide (NO) biology rather than on drug-specific mechanism data.
L-arginine is the substrate for nitric oxide synthase (nNOS) in the nitrergic neurons of the gut. NO-mediated relaxation is important for gastric accommodation and for relaxation of the pyloric sphincter. If this pathway is impaired, gastric emptying may be delayed.
Preclinical studies are consistent with this idea:
- In mice, glucocorticoid-induced gastroparesis was linked to depletion of L-arginine (PMID 25057793).
- In a Parkinson’s disease rat model, nitrergic relaxation in the pyloric sphincter was impaired (PMID 35380456).
- In diabetic BB-rats, myenteric neuropathy with altered nNOS was described (PMID 18312542).
Together these suggest that arginine supplementation is biologically plausible. However, there are no human efficacy data. The remaining retrieved papers concern gastric electrical stimulation, sacral nerve stimulation, hyperglycaemia, anaphylaxis and ghrelin, and relate to arginine only indirectly. The very high TxGNN score is a computational prediction, not evidence of clinical benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25057793 | 2014 | Animal study (mouse) | Endocrinology | Dexamethasone caused gastroparesis in mice, linked to depletion of L-arginine; effect absent in GR(dim) mice |
| 35380456 | 2022 | Animal study (rat) | Am J Physiol Gastrointest Liver Physiol | Impaired nitrergic relaxation in the pyloric sphincter of a Parkinson’s disease rat model with gastroparesis |
| 18312542 | 2008 | Animal study (rat) | Neurogastroenterol Motil | Myenteric neuropathy and nNOS changes in the jejunum of diabetic BB-rats |
| 18322959 | 2008 | Animal study (mouse) | World J Gastroenterol | Ghrelin and GHRP-6 effects on gastric motility in diabetic mice with gastroparesis (indirect relevance) |
| 21193530 | 2011 | Animal study (rodent) | Am J Physiol Gastrointest Liver Physiol | Hyperglycaemia inhibits gastric motility via nodose ganglia KATP channels (indirect relevance) |
| 19023028 | 2009 | Animal study | Am J Physiol Gastrointest Liver Physiol | Synchronised gastric electrical stimulation improved vagotomy-induced impairment of gastric accommodation via the nitrergic pathway in dogs |
| 31984783 | 2020 | Animal study (rat) | Am J Physiol Gastrointest Liver Physiol | Sacral nerve stimulation increased gastric accommodation (indirect relevance) |
| 8194696 | 1994 | Animal study (rat) | Gastroenterology | Gastric motor response to food protein-induced anaphylaxis (indirect relevance) |
| 33867519 | 2021 | Case report | Am J Case Rep | Lifestyle changes normalised serum lactate in an m.3243A>G carrier (indirect relevance) |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 10093F | Arginine 5000 | Sachets of oral powder 7.6 g containing 5 g arginine, 30 | Not available |
| 11401C | Cubitan | Oral liquid 200 mL, 24 | Not available |
Safety Considerations
No label-based warnings, contraindications or drug interaction data were available in the compiled data. Please refer to the TGA-approved Product Information (PI) for safety information.
The TxGNN knowledge graph (not label text) links arginine to the following conditions as possible contraindications. These should be treated as signals for review, not confirmed label contraindications:
- Renal: kidney disease, chronic kidney disease, chronic renal failure, end-stage renal failure, nephrolithiasis, nephrocalcinosis, acute urate nephropathy
- Acid-base and mineral metabolism: metabolic acidosis, renal tubular acidosis, acidosis disorder, hypercalcaemia, humoral hypercalcaemia of malignancy, hyperparathyroidism, osteitis fibrosa, sarcoidosis, phosphorus metabolism disorders
- Cardiovascular: heart disease, cardiovascular disease, ventricular fibrillation, digitalis poisoning
- Haematological: sickle cell anaemia, hereditary persistence of fetal haemoglobin
- Metabolic: phenylketonuria and other disorders of phenylalanine metabolism
- Other: constipation, lytic metastatic bone lesions
Many of these (particularly renal impairment, cardiac disease and electrolyte disturbance) are relevant to people with gastroparesis, so they would need careful screening in any future study.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by animal studies and general NO biology (Evidence Level L4). There are no clinical trials or human efficacy data, and the original indication, mechanism of action and label safety information are all missing from the compiled data.
To proceed, the following is needed:
- Approved indication text and PI safety information (warnings, contraindications, interactions) from the TGA/PBS sources
- Detailed mechanism of action data (for example from DrugBank)
- Human evidence, starting with a small pilot or proof-of-concept study of arginine in gastroparesis (for example, diabetic or Parkinson’s-related)
- A safety review against the knowledge-graph contraindication signals, especially renal, cardiac and electrolyte conditions
- Assessment of route and formulation suitability (currently only oral products are registered, and these may be affected by delayed gastric emptying)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.